BMJ Open (Aug 2024)

Nutritional support in hospitalised patients with diabetes and risk for malnutrition: a secondary analysis of an investigator-initiated, Swiss, randomised controlled multicentre trial

  • Philipp Schuetz,
  • Beat Mueller,
  • Nina Kaegi-Braun,
  • Zeno Stanga,
  • Bettina Keller,
  • Carla Wunderle,
  • Pascal Tribolet

DOI
https://doi.org/10.1136/bmjopen-2024-084754
Journal volume & issue
Vol. 14, no. 8

Abstract

Read online

Objectives The main objective of this study was to investigate the effects of nutritional support on mortality in hospitalised patients with diabetes and nutritional risk participating in the Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) trial.Design Secondary analysis of a Swiss-wide multicentre, randomised controlled trial.Participants Patients with diabetes and risk for malnutrition.Interventions Individualised nutritional support versus usual care.Primary outcome measure 30-day all-cause mortality.Results Of the 2028 patients included in the original trial, 445 patients were diagnosed with diabetes and included in this analysis. In terms of efficacy of nutritional therapy, there was a 25% lower risk for mortality in patients with diabetes receiving nutritional support compared with controls (7% vs 10%, adjusted HR 0.75 (95% CI 0.39 to 1.43)), a finding that was not statistically significant but similar to the overall trial effects with no evidence of interaction (p=0.92). Regarding safety of nutritional therapy, there was no increase in diabetes-specific complications associated with nutritional support, particularly there was no increase in risk for hyperglycaemia (adjusted OR 0.97, 95% CI 0.56 to 1.67 p=0.90).Conclusion Patients with diabetes and malnutrition in the hospital setting have a particularly high risk for adverse outcomes and mortality. Individualised nutritional support reduced mortality in this secondary analysis of a randomized trial, but this effect was not significant calling for further large-scale trials in this vhighly ulnerable patient population.Trial registration number NCT02517476.